Artemis Medicare Services Limited has submitted its quarterly monitoring agency report for Q3FY26, detailing the utilization of proceeds from its ₹330 crore preferential issue. The report, prepared by CARE Ratings Limited as the monitoring agency, was reviewed and approved by the company's Audit Committee on February 2, 2026.

Minimal Utilization During Q3FY26

During the quarter ended December 31, 2025, the company utilized ₹0.33 crore from the issue proceeds for general corporate purposes. This amount was specifically used to pay stamp duty on the issuance of equity shares against the conversion of compulsorily convertible debentures held by International Finance Corporation (IFC).

Issue Objectives and Progress

The preferential issue was structured with two primary objectives. The major portion of ₹320 crore was allocated to support acquisition, expansion, and capital expenditure requirements of the company and its subsidiaries. An additional ₹10 crore was designated for general corporate purposes.

Deployment of Unutilized Proceeds

The company has strategically deployed its unutilized proceeds across multiple fixed deposits with leading banks to generate returns while maintaining liquidity. The investments are spread across HDFC Bank, ICICI Bank, and Axis Bank with varying maturity dates and interest rates.

Fixed Deposit Portfolio

The total interest earned on these investments amounts to ₹8.46 crore, with ₹0.05 crore from matured fixed deposits being reinvested.

Compliance and Monitoring

CARE Ratings Limited, serving as the monitoring agency under SEBI regulations, confirmed that all utilization aligns with the disclosures in the offer document. The agency reported no deviations from the stated objectives and confirmed that the proceeds have been appropriately utilized according to the subscription agreement.

The monitoring agency noted that the stamp duty payment was initially made from the company's current account on December 2, 2025, and subsequently reimbursed from the monitoring account in the same month. This transaction was supported by appropriate documentation including chartered accountant certificates, bank statements, and management certifications.

Regulatory Framework

The report was submitted pursuant to Regulation 32(6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Regulation 162A of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018. The completion timeline for the stated objectives extends until May 15, 2026, with the company maintaining its commitment to deploy the remaining funds as per the original plan.

Artemis Medicare Services Limited has completed the allotment of equity shares under its employee stock option scheme, marking another step in its capital structure evolution. The healthcare company announced the allotment of shares to grantees who exercised their vested options under the established stock option plan.

Share Allotment Details

The company has allotted 1,05,750 equity shares under its Management Stock Option Plan-2021. These shares have been issued as fully paid-up equity shares with a face value of ₹1 each.

Impact on Share Capital

The allotment has resulted in an increase in the company's issued and paid-up equity share capital. The capital structure change reflects the exercise of vested options by eligible grantees under the stock option plan.

Share Characteristics

The newly allotted equity shares carry identical rights and privileges as existing equity shares of the company. They will rank pari-passu with the existing equity shares of the company.

Regulatory Compliance

The company has fulfilled its disclosure obligations regarding the allotment of shares under its employee stock option scheme. This action aligns with Artemis Medicare Services' commitment to employee participation in equity ownership while maintaining compliance with regulatory frameworks governing employee stock option schemes in the healthcare sector.